Invezz

ADM Q4 earnings miss estimates, DOJ probe sparks concern

ADM Q4 earnings miss estimates, DOJ probe sparks concern
Diya Poddar
Mar 12, 2024, 11:16 AM
  • Archer-Daniels-Midland Co., disclosed lower-than-expected earnings for the fourth quarter.
  • ADM reported adjusted earnings of $1.36 per share for the quarter.
  • However, the company's share price showed resilience, rising 3.4% in premarket trading.

Archer-Daniels-Midland Co. (ADM), a leading global grains merchant, disclosed lower-than-expected earnings for the fourth quarter on Tuesday.

The announcement comes after an internal investigation into the company's accounting practices caused a nearly two-month delay in the release of its financial results.

ADM reported adjusted earnings of $1.36 per share for the quarter, falling short of analysts' expectations of $1.43 per share, as per LSEG data.

DOJ investigation intensifies

The company also revealed that several of its employees have been issued subpoenas by the Department of Justice (DOJ) as part of an ongoing investigation into its accounting practices, a Reuters report said.

This follows reports of irregularities in how sales between business units were recorded, with some transactions not reflecting market value.

These discrepancies prompted adjustments to financial information in segment-specific statements for the years 2018 through 2023.

FBI involvement

Recent reports from Reuters highlighted the delivery of subpoenas by FBI agents to ADM employees in Illinois, indicating a rapid escalation of the criminal probe into the company's accounting issues.

This investigation, initially reported last month, has added a layer of uncertainty to ADM's nutrition segment.

This division has faced challenges in meeting revenue targets, compounded by slowing demand for meat alternatives and ongoing supply chain disruptions.

ADM's response to the probe

ADM has confirmed its cooperation with the DOJ, stating that the grand jury subpoenas were directed at certain current and former employees.

Despite the adjustments made to its previous financial statements, the company assures that these corrections have not impacted its consolidated financial statements for any period, as they pertain solely to inter-segment sales.

As the legal scrutiny intensifies, ADM's nutrition segment remains under pressure to achieve its financial objectives amid broader market challenges.

However, the company's share price showed resilience, rising 3.4% in premarket trading, suggesting investor confidence in ADM's ability to navigate through these complexities.